Your browser doesn't support javascript.
loading
The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization.
Eski, M T; Teberik, Kuddusi; Oltulu, Pembe; Ankarali, Handan; Kaya, Murat; Alpay, Merve.
Affiliation
  • Eski MT; 498080Private Neon Hospital, Erzincan, Turkey.
  • Teberik K; Department of Ophthalmology, Medical School, 121595Duzce University, Duzce, Turkey.
  • Oltulu P; Department of Pathology, Faculty of Medicine, 226846Necmettin Erbakan University, Konya, Turkey.
  • Ankarali H; Department of Biostatistics and Medical Informatics, Medical School, 226842Istanbul Medeniyet University, Istanbul, Turkey.
  • Kaya M; Department of Ophthalmology, Medical School, 121595Duzce University, Duzce, Turkey.
  • Alpay M; Department of Medical Biochemistry, Faculty of Medicine, 121595Duzce University, Duzce, Turkey.
Hum Exp Toxicol ; 41: 9603271221084674, 2022.
Article in En | MEDLINE | ID: mdl-35465742
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Corneal Neovascularization / Ranibizumab Type of study: Prognostic_studies Limits: Animals Language: En Journal: Hum Exp Toxicol Journal subject: TOXICOLOGIA Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Corneal Neovascularization / Ranibizumab Type of study: Prognostic_studies Limits: Animals Language: En Journal: Hum Exp Toxicol Journal subject: TOXICOLOGIA Year: 2022 Document type: Article Affiliation country: Country of publication: